Wegovy is approved for chronic weight management (2021), cardiovascular risk reduction in adults with obesity and CVD (2024), and non-cirrhotic MASH with F2-F3 fibrosis (August 2025)
While generally well-tolerated, some potential side effects or risks have been observed in GHK-Cu research, particularly with higher concentrations or in subjects with sensitive skin
Other factors such as hypertension, high cholesterol, and obstructive sleep apnea also elevate individual risk
Amorini, A
Phenobarbital: Advanced cirrhosis with hepatic encephalopathy
"For example, some plans though uncommon will only cover Ozempic if you've tried two other medications, for 120 days each, and have failed to achieve an A1C (an indication of average blood sugar levels over the past three months) of less than 7 percent." Does Medicaid cover Ozempic